NL-OMON24017招募中不适用
TREATMENT WITH CMV PP65-SPECIFIC T CELLS GENERATED BY USE OF A CMV PP65 PROTEIN-SPANNING PEPTIDE POOL IN PATIENTS WITH CMV REACTIVATION OR CMV DISEASE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION.
eiden University Mecical Center0 个研究点目标入组 15 人开始时间: 待定最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 15
研究概览
简要总结
/A
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Age 0-75 years;
- •2. Recipient of alloSCT for standard indication according to national- and European Group for blood and Marrow Transplantation-guidelines (see appendix D);
排除标准
- •1. Life expectation < 3 months;
- •2. End stage irreversible multi-system organ failure;
研究者
相似试验
进行中（未招募）
不适用
TREATMENT WITH CYTOMEGALOVIRUS (CMV) PP65 SPECIFIC LYMPHOCYTES IN PATIENTS WITH CMV REACTIVATION OR CMV DISEASE AFTER ALLOGENEIC STEM CELL TRANSPLANTATIOCMV reactivation after allogeneic stem cell transplantationEUCTR2010-024307-27-NLeiden University Medical Center
已完成
2 期
TREATMENT WITH CMV PP65 SPECIFIC T CELLS GENERATED BY USE OF A CMV PP65 PROTEIN-SPANNING PEPTIDE POOL IN PATIENTS WITH CMV REACTIVATION OR CMV DISEASE AFTER ALLOGENEIC STEM CELL TRANSPLANTATIONL-OMON36436eids Universitair Medisch Centrum16
撤回
1 期
Adoptive Transfer of pp65-specific T Cells for the Treatment of Refractory Cytomegalovirus (CMV) InfectionCytomegalovirus InfectionsNCT02346617Yae-Jean Kim
终止
1 期
CMV pp65 Specific T Cell Adoptive Immunotherapy in Allogeneic Stem Cell Transplantation for Malignant DiseaseAllogeneic Stem Cell TransplantationNCT00611637H. Kim Lyerly2
进行中（未招募）
1 期
CMV specific T cell therapy for the treatment of relapsing or therapy refractory CMV infection after allogeneic stem cell transplantation with a CMV-positive donor.EUCTR2013-004953-26-BEGhent University Hospital20